Limiting access to letrozole-is it justified?

Fertility and Sterility

Volumn 88, Issue 4, 2007, Pages 779-780

  Tulandi, Togas ^a   DeCherney, Alan H ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

aromatase inhibitor; congenital malformation; Letrozole; ovulation; ovulation induction; research; teratogenicity

Indexed keywords

CLOMIFENE CITRATE; GONADOTROPIN; GONADOTROPIN DERIVATIVE; LETROZOLE; METHANOL DERIVATIVE;

AORTA STENOSIS; CONCEPTION; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG UTILIZATION; EDITORIAL; FETUS DEVELOPMENT; HEALTH CARE ACCESS; HUMAN; INFERTILITY; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; SUPEROVULATION; TERATOGENICITY;

AROMATASE INHIBITORS; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; INFERTILITY, FEMALE; NITRILES; OVULATION INDUCTION; PREGNANCY; TRIAZOLES;

EID: 34848912242     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.01.115     Document Type: Editorial

References (6)

1. Biljan M.M., Hemmings R., and Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. [abstract]. Fertil Steril 84 Supp 1 (2005) O-231. Abstract 1033
2. Holzer H., Casper R., and Tulandi T. A new era of ovulation induction. Fertil Steril 85 (2006) 277-284
3. Fontana PG, Leclerc JM. Contraindication of Femara® (letrozole) in premenopausal women. Available at: http://www.ca.novartis.com/downloads/en/letters/femara_hcp_e_17_11_05.pdf
4. Shepard T.H. Catalog of teratogenic agents. 10th ed. (2001), Johns Hopkins University Press, Baltimore
5. Tulandi T., Martin J., Al-Fadhli R., Kabli N., Forman R., Hitkari J., et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 85 (2006) 1761-1765
6. Mitwally M.F., Biljan M.M., and Casper R.F. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 192 (2005) 381-386